Lifeboat Foundation

👉For business inquiries: [email protected].
✅ Instagram: https://www.instagram.com/pro_robots.

In the quest to overcome the limitations of the human body and mind, scientists worldwide are diligently working on various technologies. The question arises: What will human beings become after undergoing numerous enhancements? Will we retain our identity while embracing the possibilities offered by artificial intelligence? What extraordinary capabilities will biotechnology bestow upon us? And how will our emotions and desires evolve as our bodies undergo transformation?

Continue reading “Humanity in 2050” »

Artificial intelligence is changing health care. It promises better diagnoses and fewer mistakes and all in less time. While some associate AI with a frightening dystopian future, many doctors see it as a source of support.

To help them care for patients, doctors are programming apps and supplying AI with data. At Berlin’s Charité hospital, Professor Surjo Soekadar is researching how neurotechnology might support paralysis patients in their everyday lives — for example, via assistance systems that are controlled via their thoughts.

Continue reading “Doctors, apps and artificial intelligence — The future of medicine” »

A process of surgically joining the circulatory systems of a young and old mouse has been found to slow aging at a cellular level and extend the older animal’s life by as much as 10%.

Recently published in Nature Aging, a study led by researchers from Duke Health discovered the longer the animals shared circulation, the longer the anti-aging benefits lasted once the two were no longer connected.

The findings suggest that the young benefit from a cocktail of components and chemicals in their blood that contribute to vitality, and these factors could potentially be isolated as therapies to speed healing, rejuvenate the body, and add years to an older individual’s life.

Would you want to live forever? On this episode, Neil deGrasse Tyson and author, inventor, and futurist Ray Kurzweil discuss immortality, longevity escape velocity, the singularity, and the future of technology. What will life be like in 10 years?

Could we upload our brain to the cloud? We explore the merger of humans with machines and how we are already doing it. Could nanobots someday flow through our bloodstreams? Learn about the exponential growth of computation and what future computing power will look like.

Continue reading “Ray Kurzweil Wants To Put Nanobots In Our Bloodstream” »

Aging is a major risk factor for most chronic conditions, evidence shows, yet much of current research focuses on addressing specific diseases. The new translational geroscience initiative at Yale School of Medicine (YSM) seeks to change that approach by studying the effects of aging on various ailments.

“Yale School of Medicine has a long legacy in studying aging, but with this new initiative we are bolstering our ability to delineate basic mechanisms of healthy and accelerated aging,” said Nancy J. Brown, MD, Jean and David W. Wallace Dean of the Yale School of Medicine and C.N.H. Long Professor of Internal Medicine.

The mechanisms underlying the aging process are often also driving the development and progression of chronic conditions, explains Thomas Gill, MD, Humana Foundation Professor of Medicine (Geriatrics) and professor of epidemiology, Yale School of Public Health, and of investigative medicine at YSM, who leads the Yale Pepper Older Americans Independence Center.

Venture Investing To Catalyze The Next Generation Of Founder-Led, Longevity Biotech Companies — Dr. Alex Colville, Ph.D., Co-Founder and General Partner — age1.

Dr. Alex Colville, Ph.D. is Co-Founder and General Partner of age1 (https://age1.com/), a venture capital firm focused on catalyzing the next generation of founder-led, longevity biotech companies, with a strategy of building a community of visionaries advancing new therapeutics, tools, and technologies targeting aging and age-related diseases.

Continue reading “Dr. Alex Colville, Ph.D. — Co-Founder and General Partner — age1” »

150 YEARS MAXIMUM BIOLOGICAL AGE — “We observed, that the age-dependent population DOSI distribution broadening could be explained by a progressive loss of physiological resilience measured by the DOSI auto-correlation time. Extrapolation of this trend suggested that DOSI recovery time and variance would simultaneously diverge at a critical point of 120 − 150 years of age corresponding to a complete loss of resilience. The observation was immediately confirmed by the independent analysis of correlation properties of intraday physical activity levels fluctuations collected by wearable devices. We conclude that the criticality resulting in the end of life is an intrinsic biological property of an organism that is independent of stress factors and signifies a fundamental or absolute limit of human lifespan.”

We investigated the dynamic properties of the organism state fluctuations along individual aging trajectories in a large longitudinal database of CBC measurements from a consumer diagnostics laboratory. To simplify the analysis, we used a log-linear mortality estimate from the CBC variables as a single quantitative measure of aging process, henceforth referred to as dynamic organism state index (DOSI). We observed, that the age-dependent population DOSI distribution broadening could be explained by a progressive loss of physiological resilience measured by the DOSI auto-correlation time. Extrapolation of this trend suggested that DOSI recovery time and variance would simultaneously diverge at a critical point of 120 − 150 years of age corresponding to a complete loss of resilience. The observation was immediately confirmed by the independent analysis of correlation properties of intraday physical activity levels fluctuations collected by wearable devices. We conclude that the criticality resulting in the end of life is an intrinsic biological property of an organism that is independent of stress factors and signifies a fundamental or absolute limit of human lifespan.

P.O. Fedichev is a shareholder of Gero LLC. A.Gudkov is a member of Gero LLC Advisory Board. T.V. Pyrkov, K. Avchaciov, A.E. Tarkhov, L. Menshikov, and P.O. Fedichev are employees of Gero LLC.

Researchers at ETH Zurich recently identified a previously unknown compartment in mammalian cells. They have named it the exclusome. It is made up of DNA rings known as plasmids. The researchers have published details of their discovery in the journal Molecular Biology of the Cell.

The new compartment is in the cell plasma; it is previously uncharacterized in the literature. It is exceptional because eukaryotic cells (cells with nuclei) usually keep most of their DNA in the cell nucleus, where it is organized into chromosomes.

Some of the plasmids that end up in the exclusome originate from outside the cell, while others—known as telomeric rings—come from the capped ends of chromosomes, the telomeres. Particularly in certain cancer cells, the ones from the telomeres are regularly pinched off and joined together to form rings. However, these don’t contain the blueprints for proteins.

George Church at his most optimistic. June 1, 2022.

Dr George Church talks about combination therapies for age reversal, recently published papers from his lab and expresses his wish on developing inexpensive gene therapies like vaccine that can be equitably distributed to human.

Continue reading “Targeting A $2 Dose AGING REVERSAL Therapy For Everyone” »